Abstract
Selective occlusion of tumor vasculature was tested as a therapy for solid tumors in a mouse model. The formation of blood clots (thrombosis) within the tumor vessels was initiated by targeting the cell surface domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker on tumor vascular endothelial cells. This truncated form of tissue factor (tTF) had limited ability to initiate thrombosis when free in the circulation, but became an effective and selective thrombogen when targeted to tumor endothelial cells. Intravenous administration of the antibody-tTF complex to mice with large neuroblastomas resulted in complete tumor regressions in 38 percent of the mice.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies / immunology
-
Blood Coagulation*
-
Endothelium, Vascular / immunology
-
Histocompatibility Antigens Class II / immunology
-
Histocompatibility Antigens Class II / metabolism
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / metabolism
-
Immunoconjugates / therapeutic use*
-
Injections, Intravenous
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Neuroblastoma / blood supply*
-
Neuroblastoma / drug therapy*
-
Neuroblastoma / pathology
-
Thromboplastin / administration & dosage
-
Thromboplastin / metabolism
-
Thromboplastin / therapeutic use*
-
Tumor Cells, Cultured
Substances
-
Antibodies
-
Histocompatibility Antigens Class II
-
Immunoconjugates
-
Thromboplastin